Navigation Links
Nektar to Announce Financial Results for the First Quarter of 2013 on Thursday, May 9, 2013, After Close of U.S.-Based Financial Markets
Date:5/2/2013

, which has completed Phase 3 development as a once- daily, oral tablet for the treatment of opioid-induced constipation.  This agreement also includes NKTR-119, an earlier stage development program that is a co-formulation of naloxegol and an opioid.  NKTR-181, a novel mu-opioid analgesic candidate for chronic pain conditions, is in Phase 2 development in osteoarthritis patients with chronic knee pain.  NKTR-192, a novel mu-opioid analgesic in development to treat acute pain is in Phase 1 clinical development.  In oncology, etirinotecan pegol (NKTR-102) is being evaluated in a Phase 3 clinical study (the BEACON study) for the treatment of metastatic breast cancer and is also in Phase 2 studies for the treatment of ovarian and colorectal cancers. In anti-infectives, Amikacin Inhale is in Phase 3 studies conducted by Bayer Healthcare to treat patients with Gram-negative pneumonia.

Nektar's technology has enabled eight approved products in the U.S. or Europe through partnerships with leading biopharmaceutical companies, including UCB's Cimzia® for Crohn's disease and rheumatoid arthritis, Roche's PEGASYS® for hepatitis C and Amgen's Neulasta® for neutropenia.  Additional development-stage products that leverage Nektar's proprietary technology platform include Baxter's BAX 855, a long-acting PEGylated rFVIII program, which is in Phase 3 clinical development.

Nektar is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India.  Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com.


'/>"/>
SOURCE Nektar Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Nektar to Announce Financial Results for the First Quarter of 2012 on Wednesday, May 2, 2012, After Close of U.S.-Based Financial Markets
2. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
3. Nektar Therapeutics President and CEO Howard W. Robin to Present at the Jefferies 2012 Global Healthcare Conference in New York
4. Nektar Announces that FDA Grants Fast Track Designation to NKTR-181, a New Oral Opioid Analgesic Molecule, for the Treatment of Moderate to Severe Chronic Pain
5. Nektar Announces Start of Enrollment in Phase 2 Study of NKTR-181, a Novel Opioid Analgesic Molecule, for Treatment of Chronic Pain
6. Nektar Announces Initiation of Investigator-Sponsored Trial Evaluating Etirinotecan Pegol (NKTR-102) in Patients with Bevacizumab (Avastin)-resistant High-Grade Glioma
7. Nektar Therapeutics Reports Financial Results for the Second Quarter of 2012
8. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the UBS 2012 Global Life Sciences Conference in New York City
9. Nektar to Announce Financial Results for the Third Quarter of 2012 On Tuesday, November 13, 2012, After Close of U.S.-Based Financial Markets
10. Nektar Announces that FDA Grants Fast Track Designation to Etirinotecan Pegol (NKTR-102) for the Treatment of Metastatic Breast Cancer
11. Nektar To Host Conference Call To Discuss The Positive Phase 3 Clinical Results For Naloxegol
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... July 29, 2015   Decision Resources Group ... Europe will continue to be hindered ... the Eurozone. On a longer timeline, however, the outlook ... physically active will increase the prevalence of osteoarthritic damage ... and orthopedic soft tissue solutions. Coupled with continuing economic ...
(Date:7/29/2015)... REDMOND, Washington , 29. Juli 2015 ... deutschen Diabeteszentrums wurde festgestellt, dass die tägliche ... von Nutraceutix die menschliche Darmflora anreichert und ... Insulinsekretion erhöhen. Die Studie umfasste die tägliche ... (ATCC-Stamm SD-5865) in Tablettenform unter Verwendung der ...
(Date:7/29/2015)... INCLINE VILLAGE, Nev. , July 29, 2015 /PRNewswire/ ... that it has entered into a revenue interest assignment ... provide ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA ) with ... exchange for royalties on the net revenues of Iclusig ... will be made in two tranches of $50 million ...
Breaking Medicine Technology:The Long-Term Outlook for European Sports Medicine Device Markets Remains Positive, with Economic Recovery and Expanding Patient Populations Supporting Growth Through 2023 2The Long-Term Outlook for European Sports Medicine Device Markets Remains Positive, with Economic Recovery and Expanding Patient Populations Supporting Growth Through 2023 3Klinischer Nachweis erbracht, dass L. reuteri Probiotikum von Nutraceutix den Darm-Insulinmetabolismus moduliert 2PDL BioPharma Completes Royalty Transaction with ARIAD Pharmaceuticals 2PDL BioPharma Completes Royalty Transaction with ARIAD Pharmaceuticals 3PDL BioPharma Completes Royalty Transaction with ARIAD Pharmaceuticals 4PDL BioPharma Completes Royalty Transaction with ARIAD Pharmaceuticals 5
... Day Schedule -- SHANGHAI, Sept. 3 /PRNewswire-Asia-FirstCall/ -- ... ... ... ,; var first_result; // Results are keyed by longUrl, so we need to grab the first one. ...
... Treatment TMC278 -- CORK, Ireland, September 3, 2010 ... ... --> ... = ,; var first_result; // Results are keyed by longUrl, so we need to grab the first ...
Cached Medicine Technology:China-Biotics Announces September 20 Investor Day Schedule 2China-Biotics Announces September 20 Investor Day Schedule 3China-Biotics Announces September 20 Investor Day Schedule 4China-Biotics Announces September 20 Investor Day Schedule 5China-Biotics Announces September 20 Investor Day Schedule 6China-Biotics Announces September 20 Investor Day Schedule 7Tibotec Pharmaceuticals Seeks European Marketing Authorization for Investigational Once-Daily HIV Treatment TMC278 2Tibotec Pharmaceuticals Seeks European Marketing Authorization for Investigational Once-Daily HIV Treatment TMC278 3Tibotec Pharmaceuticals Seeks European Marketing Authorization for Investigational Once-Daily HIV Treatment TMC278 4Tibotec Pharmaceuticals Seeks European Marketing Authorization for Investigational Once-Daily HIV Treatment TMC278 5Tibotec Pharmaceuticals Seeks European Marketing Authorization for Investigational Once-Daily HIV Treatment TMC278 6Tibotec Pharmaceuticals Seeks European Marketing Authorization for Investigational Once-Daily HIV Treatment TMC278 7Tibotec Pharmaceuticals Seeks European Marketing Authorization for Investigational Once-Daily HIV Treatment TMC278 8
(Date:7/29/2015)... ... 2015 , ... Gender minority people who are transgender or ... provided legal protections against discrimination on the basis of gender identity in employment, ... based on gender identity in places open to the public, such as transportation, ...
(Date:7/29/2015)... ... ... " Core Organizer ” was featured on NewsWatch as part of its monthly ... for iOS, Android, and Windows. Joe Toohey, the host of AppWatch and technology expert, ... get organized. , Wouldn’t it be great if everyone could be a little more ...
(Date:7/29/2015)... , ... July 29, 2015 , ... Join Luz Delia ... healthfulness. Gerber believes that Well-Being begins with understanding how the body actually works. A ... of healthfulness within. Guests will receive tips on how to forge this new relationship ...
(Date:7/29/2015)... ... ... Ticket Down is a reliable source of authentic tickets for the international ... The international soccer schedule of matches played on American soil continues to grow each ... the world’s greatest teams, Brazil, will travel to North America to compete with the ...
(Date:7/29/2015)... NJ (PRWEB) , ... July 29, 2015 , ... ... (the Commission) CCM® credential for a five-year period, expiring November 30, 2019, during ... CCM credential by submitting an application demonstrating the program’s compliance with the NCCA’s ...
Breaking Medicine News(10 mins):Health News:Fenway Health Researcher: Legal Protections in Public Settings are a Critical Public Health Issue for Transgender and Gender-Nonconforming People 2Health News:Fenway Health Researcher: Legal Protections in Public Settings are a Critical Public Health Issue for Transgender and Gender-Nonconforming People 3Health News:Get More Organized with the Core Organizer App 2Health News:Pampering and Empowerment Abound at Final Event in Luz Delia Gerber’s Book Unveiling 2Health News:Cheap USA vs. Brazil Tickets at Gillette Stadium: Ticket Down Cuts Presale Ticket Prices for Brazil vs. USA Men's National Soccer Team (USMNT) at Gillette Stadium 2Health News:Cheap USA vs. Brazil Tickets at Gillette Stadium: Ticket Down Cuts Presale Ticket Prices for Brazil vs. USA Men's National Soccer Team (USMNT) at Gillette Stadium 3Health News:Commission for Case Manager Certification Receives Re-Accreditation of its CCM® credential from the National Commission for Certifying Agencies (NCCA) 2Health News:Commission for Case Manager Certification Receives Re-Accreditation of its CCM® credential from the National Commission for Certifying Agencies (NCCA) 3
... Quality,Respiratory Care (CQRC) expressed extreme concern and disappointment ... for Medicare and Medicaid,Services (CMS) implementing the Deficit ... oxygen therapy. With the January 1, 2009,implementation date ... guidance on how Medicare will cover the costs ...
... new report shows many are cutting,back on health ... ways to get the,most out of your health ... Listen to this report from CIGNA at:, ... audio, text, graphics and,photos for free and unrestricted ...
... hair cells from pumping out excess calcium, study finds , , ... that mimics progressive hearing loss in humans has been identified ... mutation in a gene called Oblivion had problems with the ... with one mutant copy of the Oblivion gene, ear hair ...
... increases in surgical capacity or diverting patients to other ... wait times for hip and knee replacement surgery ... , Politically popular strategies, such ... much impact, according to a new study. Instead, the ...
... where people have to opt out of donating their organs when ... waiting list for transplant. , That is the opinion of Dr ... of body parts, who has recently joined the University of Bath,s ... patients in the UK currently on the waiting list for organ ...
... Impact of McCain, Obama,Proposals, WASHINGTON, Oct. 31 ... and costs are continuing to skyrocket --,making health care ... United States., A detailed analysis of each candidate,s ... government is included in the Guide to,Healthcare: The 2008 ...
Cached Medicine News:Health News:Council for Quality Respiratory Care Statement 2Health News:Mutant Mouse Gene Offers Clues to Hearing Loss 2Health News:Wait time guarantees not likely to reduce waits for joint replacement surgery 2Health News:'Opt out' system could solve donor organ shortage, says researcher 2Health News:Candidates' Proposals to Address Health Care Cost, Coverage and Quality Come at Major Costs 2Health News:Candidates' Proposals to Address Health Care Cost, Coverage and Quality Come at Major Costs 3
... Thalia eyeglasses eyewear collection reflects ... of the renowned Latin singer/actress ... eyeglasses eyewear is ultra-sleek, fashionable, ... styles that include decorative details ...
... Vera Wang Eyewear, a dainty, feminine collection ... launched in the UK by The Norville ... sensuous curves of Vera Wang Eyewear bring ... fine quality materials such as stainless steel, ...
... care is something that almost all retailers ... these needs with VALUE - not just ... design. Jobson Research shows that National is ... care product., ,National offers an exciting collection ...
... Eyewear Collection reflects the ... elegance, refinement and comfort ... dedication to quality and ... of the Lacoste brand, ...
Medicine Products: